Home Current Issue Previous Issues Published Ahead-of-Print For Authors Journal Info
Skip Navigation LinksHome > May 2008 - Volume 335 - Issue 5 > Successful Treatment of Catastrophic Antiphospholipid Antibo...
The American Journal of the Medical Sciences:
May 2008 - Volume 335 - Issue 5 - pp 394-397
doi: 10.1097/MAJ.0b013e31815203ad
Case Reports

Successful Treatment of Catastrophic Antiphospholipid Antibody Syndrome (CAPS) Associated With Splenic Marginal-zone Lymphoma With Low-molecular Weight Heparin, Rituximab and Bendamustine

MANNER, HENDRIK MD; JUNG, BERND MD; TONASSI, LEONHARD MD; HACKENBERG, ULRICH MD; PLUM, NICOLA MD; JOSTEN, KLAUS M. MD; KIRCHMAIER, CARL M. MD, PhD; FRICKHOFEN, NORBERT MD, PhD

Collapse Box

Abstract

Case report: A 69-year-old woman with splenic marginal-zone lymphoma was admitted with progressive abdominal pain and splenomegaly as the suspected cause of pain. Rituximab treatment (375 mg/m2) had been initiated on the day of admission. Abdominal computerized tomography revealed splenic infarction. Laboratory tests showed elevation of liver enzymes and creatinine, low platelet count, prolonged partial thromboplastin time, and lupus anticoagulant positivity. The diagnosis of catastrophic antiphospholipid antibody syndrome was made. Weight-adjusted low-molecular weight heparin therapy was initiated. Freedom from symptoms and normalization of liver enzymes and creatinine occurred within 4 weeks. Treatment was continued with 6 cycles of bendamustine monotherapy (90 mg/m2) and heparin, leading to partial remission of lymphoma and lupus anticoagulant negativity.

Conclusions: In case of multiorgan failure in patients suffering from lymphoma and showing features of disseminated intravascular coagulation, catastrophic antiphospholipid antibody syndrome should be considered. In our patient, rituximab followed by weight-adjusted low-molecular weight heparin and bendamustine therapy led to recovery.

© Copyright 2008 Southern Society for Clinical Investigation

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Article Tools

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.